• 繁

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    How Phase 2 Vaccine Results At Pfizer (PFE) Has Changed Its Investment Story

    Simply Wall St·10/25/2026 00:43:16
    語音播報
    • Pfizer reported detailed Phase 2 data for its 25-valent pneumococcal conjugate vaccine in infants, showing robust immune responses across all 25 serotypes with safety and tolerability comparable to PREVNAR 20. The company is moving ahead with multiple pediatric Phase 3 trials and a separate 35-valent adult program.
    • The vaccine candidate uses next-generation technology that produced much higher antibody levels against serotype 3 and adds five serotypes estimated to account for about 30% of additional pediatric invasive pneumococcal disease cases in the U.S. This underscores how Pfizer is trying to widen its pediatric vaccine coverage within its broader shift toward non COVID products.
    • We will look at how Pfizer’s investment narrative evolves as this 25-valent infant vaccine advances with stronger serotype 3 immune responses.
    Spot under-the-radar vaccine and infectious disease plays that echo Pfizer’s R&D push by checking our hand picked list of 34 healthcare AI stocks.

    Pfizer Investment Narrative Recap

    For a shareholder in Pfizer, the core belief is that management can replace declining COVID revenue with a mix of vaccines, oncology and obesity drugs, while keeping margins supported by the planned US$9.7b in savings through 2029. The recent 25 valent pneumococcal data reinforces that vaccines remain a meaningful part of that non COVID shift, even if this single trial does not transform near term numbers.

    The short term swing factor is execution on launches and cost cuts at a time when profit margins are already thinner and debt is elevated. The biggest risk stays the same: pipeline or pricing setbacks that slow non COVID products just as COVID sales and one off items leave earnings looking more fragile, especially with a dividend that current earnings do not fully cover.

    The IDWeek 2026 data package around infectious diseases sits closest to this pneumococcal update. It shows Pfizer working across COMIRNATY, ABRYSVO, PREVNAR 20 and PENBRAYA, rather than relying on a single shot to carry the vaccine franchise. That breadth matters if you are counting on vaccines to help offset loss of exclusivity and the COVID reset.

    This breadth also sharpens the execution bar. Each program carries its own regulatory and reimbursement risks, and real world effectiveness work on ABRYSVO and PREVNAR 20 needs to translate into durable demand to support the investment case. For investors tracking catalysts, the Phase 3 pneumococcal readouts and ongoing ID portfolio data look like practical checkpoints on whether Pfizer’s infectious disease engine is doing its part in the wider turnaround story.

    Pfizer's current analyst storyline points to US$54.3b in revenue and US$9.1b in earnings by 2029, built on an assumed 5.2% yearly decline in sales and a move from US$4.3b in earnings today to the 2029 consensus figure. This implies roughly a doubling of profit over that period.

    Uncover how Pfizer's fair value indicates a 4% potential downside to its current price, leaving little room for error.

    NYSE:PFE 1-Year Stock Price Chart
    NYSE:PFE 1-Year Stock Price Chart

    Exploring Other Perspectives

    You might see this Pfizer update very differently depending on which analysts you follow. The most optimistic group treated pipeline execution as the real catalyst, with 2029 earnings forecasts around US$12.6b versus the more cautious US$9.1b view. Those pre news estimates could shift as the 25 valent vaccine story filters into new models.

    Explore 10 other Pfizer fair value estimates, including one that suggests as much as 145% upside from the current price.

    The Verdict Is Yours

    Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.

    Looking For More Investment Ideas Beyond Pfizer?

    Once you have a handle on Pfizer, it can help to widen the lens and compare it with other opportunities that fit different risk and income profiles using the Simply Wall St Screener.

    • If you care most about quality at a sensible entry point, scan for companies with strong fundamentals that currently look inexpensive using our 27 high quality undervalued stocks.
    • If capital preservation and balance sheet strength matter more to you than headline growth, filter for resilient businesses with modest risk profiles through the 30 resilient stocks with low risk scores.
    • If you are hunting for lesser known ideas with solid numbers behind them, sort through a 21 high quality undiscovered gems that might not be on every investor's radar yet.